Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Cash (2021 - 2025)

Krystal Biotech's Change in Cash history spans 5 years, with the latest figure at $103.7 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 456.35% year-over-year to $103.7 million; the TTM value through Dec 2025 reached $151.4 million, up 1224.85%, while the annual FY2025 figure was $151.4 million, 1224.85% up from the prior year.
  • Change in Cash for Q4 2025 was $103.7 million at Krystal Biotech, up from $38.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $135.1 million in Q2 2023 and bottomed at -$72.6 million in Q2 2021.
  • The 5-year median for Change in Cash is -$14.1 million (2023), against an average of $11.4 million.
  • The largest YoY upside for Change in Cash was 456.35% in 2025 against a maximum downside of 5423.75% in 2025.
  • A 5-year view of Change in Cash shows it stood at $54.6 million in 2021, then tumbled by 144.86% to -$24.5 million in 2022, then soared by 39.15% to -$14.9 million in 2023, then plummeted by 95.14% to -$29.1 million in 2024, then skyrocketed by 456.35% to $103.7 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Change in Cash are $103.7 million (Q4 2025), $38.8 million (Q3 2025), and $45.1 million (Q2 2025).